Ayse Altintas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6474703/publications.pdf

Version: 2024-02-01

		186265	149698
73	3,273	28	56
papers	citations	h-index	g-index
75	75	75	3973
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain, 2008, 131, 1759-1775.	7.6	402
2	Beh�et's disease: diagnostic and prognostic aspects of neurological involvement. Journal of Neurology, 2001, 248, 95-103.	3.6	276
3	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	3.0	249
4	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1005-1015.	1.9	228
5	Beh??et??s syndrome and the nervous system. Current Opinion in Neurology, 2004, 17, 347-357.	3.6	156
6	Fatigue and sleep disturbance in multiple sclerosis. European Journal of Neurology, 2006, 13, 1333-1339.	3.3	143
7	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1802-1809.	3.0	133
8	Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. Multiple Sclerosis Journal, 2012, 18, 1448-1453.	3.0	116
9	Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Multiple Sclerosis Journal, 2014, 20, 1086-1094.	3.0	87
10	Neurofilament ELISA validation. Journal of Immunological Methods, 2010, 352, 23-31.	1.4	86
11	Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease. Multiple Sclerosis Journal, 2009, 15, 918-927.	3.0	80
12	Headache in Behçet's Syndrome. Headache, 2005, 45, 911-919.	3.9	76
13	Association of <i>APOE</i> polymorphisms with disease severity in MS is limited to women. Neurology, 2004, 62, 811-814.	1.1	75
14	Familial occurrence and heritable connective tissue disorders in cervical artery dissection. Neurology, 2014, 83, 2023-2031.	1.1	74
15	<i>CADISP-Genetics</i> : An International Project Searching for Genetic Risk Factors of Cervical Artery Dissections. International Journal of Stroke, 2009, 4, 224-230.	5.9	68
16	Treatment of MOG antibody associated disorders: results of an international survey. Journal of Neurology, 2020, 267, 3565-3577.	3.6	64
17	Bone status in multiple sclerosis: beyond corticosteroids. Multiple Sclerosis Journal, 2003, 9, 600-604.	3.0	62
18	Sex effects across the lifespan in women with multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093616.	3.5	58

#	Article	IF	CITATIONS
19	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Multiple Sclerosis Journal, 2020, 26, 912-923.	3.0	52
20	Risk of secondary progressive multiple sclerosis: A longitudinal study. Multiple Sclerosis Journal, 2020, 26, 79-90.	3.0	52
21	Retinal Optical Coherence Tomography in Neuromyelitis Optica. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	47
22	Pulmonary function in multiple sclerosis without any respiratory complaints. Clinical Neurology and Neurosurgery, 2007, 109, 242-246.	1.4	41
23	Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: Favorable response to cancer treatment. Journal of Spinal Cord Medicine, 2012, 35, 267-269.	1.4	33
24	Hepatitis B vaccine related-myelitis?*. European Journal of Neurology, 2001, 8, 711-715.	3.3	32
25	The role of osteopontin: A shared pathway in the pathogenesis of multiple sclerosis and osteoporosis?. Journal of the Neurological Sciences, 2009, 276, 41-44.	0.6	32
26	Early clinical markers of aggressive multiple sclerosis. Brain, 2020, 143, 1400-1413.	7.6	32
27	Original article Evaluation of oxidative and nitrosative stress in relapsing remitting multiple sclerosis: effect of corticosteroid therapy. Folia Neuropathologica, 2013, 1, 58-64.	1.2	31
28	Magnetic resonance imaging of rheumatoid meningitis: a case report and literature review. Rheumatology International, 2012, 32, 3679-3681.	3.0	30
29	Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks. Multiple Sclerosis International, 2016, 2016, 1-8.	0.8	30
30	Breathing-enhanced upper extremity exercises for patients with multiple sclerosis. Clinical Rehabilitation, 2007, 21, 595-602.	2.2	29
31	Clinical and therapeutic predictors of disease outcomes in AQP4-lgG+ neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 38, 101868.	2.0	29
32	An Association between Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis and Human Leukocyte Antigens. Epilepsia, 2002, 43, 236-239.	5.1	25
33	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756.	7.6	24
34	Next generation sequencing analysis of patients with familial cervical artery dissection. European Stroke Journal, 2017, 2, 137-143.	5.5	23
35	Factors Predictive of Severe Multiple Sclerosis Disease Reactivation After Fingolimod Cessation. Neurologist, 2018, 23, 12-16.	0.7	23
36	Gender issues of antibody-mediated diseases in neurology: (NMOSD/autoimmune encephalitis/MG). Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642094980.	3.5	23

#	Article	IF	Citations
37	Longitudinal Retinal Changes in <scp>MOGAD</scp> . Annals of Neurology, 2022, 92, 476-485.	5. 3	20
38	Pregnancy Data in a Turkish Multiple Sclerosis Population. European Neurology, 2015, 74, 296-302.	1.4	19
39	Arthritis during interferon beta-1b treatment in multiple sclerosis. Multiple Sclerosis Journal, 2002, 8, 534-536.	3.0	17
40	Prognostic significance of pulsatile tinnitus in cervical artery dissection. European Journal of Neurology, 2016, 23, 1183-1187.	3.3	17
41	Identification of 3 Novel Patients with <i>CLCN2</i> -Related Leukoencephalopathy due to <i>CLCN2</i> Mutations. European Neurology, 2017, 78, 125-127.	1.4	16
42	Dysfunction of CD3 \hat{a} CD16 + CD56 dim and CD3 \hat{a} CD16 \hat{a} CD56 bright NK cell subsets in RR-MS patients. Clinical Immunology, 2018, 193, 88-97.	3.2	16
43	Astrocytic outer retinal layer thinning is not a feature in AQP4-lgG seropositive neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 188-195.	1.9	13
44	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 755-766.	3.0	11
45	CD3-CD56+ NK cells display an inflammatory profile in RR-MS patients. Immunology Letters, 2019, 216, 63-69.	2.5	10
46	Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype. Multiple Sclerosis Journal, 2020, 26, 1765-1774.	3.0	10
47	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). BMJ Open, 2020, 10, e035397.	1.9	10
48	A cerebellar demyelinating lesion following treatment of acne with isotretinoin. Clinical and Experimental Dermatology, 2008, 33, 118-121.	1.3	9
49	The Complex Genetic Landscape of Hereditary Ataxias in Turkey and Implications in Clinical Practice. Movement Disorders, 2021, 36, 1676-1688.	3.9	9
50	Pathological Contrast Enhancement of the Oculomotor and Trigeminal Nerves Caused by Intracranial Hypotension Syndrome. Headache, 2011, 51, 804-808.	3.9	8
51	Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort. Neurologist, 2015, 20, 61-66.	0.7	8
52	Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009–2018. CNS Drugs, 2021, 35, 1097-1106.	5.9	7
53	Treatment response score to glatiramer acetate or interferon beta-1a. Neurology, 2020, 96, 10.1212/WNL.000000000010991.	1.1	6
54	The MSBase pregnancy, neonatal outcomes, and women's health registry. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110091.	3.5	6

#	Article	IF	CITATIONS
55	The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?. Multiple Sclerosis and Related Disorders, 2022, 58, 103399.	2.0	6
56	The use of Modified Rio score for determining treatment failure in patients with multiple sclerosis: retrospective descriptive case series study. Acta Neurologica Belgica, 2021, 121, 1693-1698.	1.1	5
57	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. NeuroImage: Clinical, 2021, 32, 102802.	2.7	5
58	Comparative analysis of fingolimod versus teriflunomide in relapsing–remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 36, 101376.	2.0	4
59	Sciatic neuropathy developed after injection during curettage. Agri Dergisi, 2016, 28, 46-48.	0.2	4
60	State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis. Neurology and Therapy, 2020, 9, 281-300.	3.2	3
61	H1N1 (Domuz Gribi) Aşısını Takiben Ortaya Çıkan Narkolepsi-Katapleksi Sendromu Olgularl. Noropsikiy Arsivi, 2014, 51, 283-287.	atri 0.7	3
62	Catastrophic presentation of a patient with combined NMOSD and thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a case report. Acta Neurologica Belgica, 2017, 117, 757-759.	1.1	2
63	Cytokine Polymorphism and HLA Genotyping in Patients with Temporal Lobe Epilepsy Related to Hippocampal Sclerosis. Noropsikiyatri Arsivi, 2017, 54, 350-353.	0.3	2
64	Özel Durumlarda MultiplSkleroz'lu Hastaya Yaklaşım. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2013, 19, 77-84.	0.3	1
65	Assessment of aquaporin-4 (AQP4) antibody assays in European diagnostic centres. Journal of Neuroimmunology, 2014, 275, 15.	2.3	1
66	CLIPPERS syndrome: Case report. Journal of Neuroimmunology, 2014, 275, 95.	2.3	1
67	BAb and MxA as Functional Biomarkers in Routine Clinical Laboratories for the Determination of Anti-IFN-Beta Antibodies and Their Bioactivity Levels in Multiple Sclerosis Patients. Journal of Immunoassay and Immunochemistry, 2014, 35, 398-411.	1.1	1
68	NMOSD with an unusual cerebral radiologic manifestation. Multiple Sclerosis and Related Disorders, 2016, 7, 74-75.	2.0	1
69	A novel investigation method for axonal damage in neuromyelitis optica spectrum disorder: In vivo corneal confocal microscopy. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732199806.	1.0	1
70	Letter to the Editor. Multiple Sclerosis Journal, 2000, 6, 364-364.	3.0	0
71	A Multicenter International Study to Evaluate Different Aspects of Relationship Between MS and Pregnancy. Multiple Sclerosis and Related Disorders, 2020, 37, 101537.	2.0	O
72	A 52-Year-Old Man With Progressive Weakness and Incontinence. Neurohospitalist, The, 2022, 12, 194187442110395.	0.8	0

AYSE ALTINTAS

#	Article	IF	CITATIONS
73	A case of radiologically isolated syndrome developing Balo's concentric sclerosis lesions on long-term follow-up. Neuroimmunology Reports, 2022, 2, 100093.	0.4	0